We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Adrian
Martineau
a.martineau@qmul.ac.uk
Dr
Adrian
Martineau
a.martineau@qmul.ac.uk
Tuberculosis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Tuberculosis (TB),an infectious disease caused by bacteria (bugs),is passed on when a patient with active lung TB coughs bugs into the air,which are then breathed in by an uninfected person. 90% of people with dormant infection never fall ill with active TB disease whereas 10% of them will eventually go on to develop active TB disease. Dormant TB infection can be treated with a 3-month course of antibiotics to prevent the development of active TB. Existing tests can’t distinguish the 90% of people with dormant TB infection who will never develop active TB (and who don’t need antibiotics) from the 10% who will go on to fall ill with active TB at some point in the future (who do need antibiotics). So we end up giving antibiotics to many more people than we need to.
Recently,a group of scientists in Germany have developed a sensitive new blood test that was able to detect very small numbers of TB bugs in the blood of just seven people with dormant TB infection. This finding has created a lot of excitement in the TB field,as nobody has been able to find TB bugs in people with dormant infection before. Our research study will evaluate this new blood test in a larger group of 100 asymptomatic adults from London,with and without dormant TB infection,to see if the findings from Germany are really true. As part of this study,we will also check if the test is positive in a group of patients with proven active lung TB (n=20). Asymptomatic adults will be followed for 3 months while TB patients will be followed until they complete antibiotic treatment for TB. Participants will give blood samples twice (when they enter and complete the study).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
i) For LTBI screenees • Known HIV infection • Declines HIV testing • Previous antimicrobial treatment for active TB or latent TB infection • Clinical suspicion of active TB • Already initiated chemoprophylaxis ii) For adults with active TB • Known HIV infection • Declines HIV testing • Already initiated anti-TB treatment • Haemoglobin concentration <10 g/dl at screening
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Queen Mary University of London and funded by Asthma and Lung UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 59558
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
